Literature DB >> 31082473

Gonadal Function after Busulfan Compared with Treosulfan in Children and Adolescents Undergoing Allogeneic Hematopoietic Stem Cell Transplant.

Maura Faraci1, Tamara Diesch2, Myriam Labopin3, Arnaud Dalissier4, Arian Lankester5, Andrew Gennery6, Mikael Sundin7, Duygu Uckan-Cetinkaya8, Marc Bierings9, Anke M J Peters10, Martina Garwer11, Ansgar Schulz12, Gerard Michel13, Giovanna Giorgiani14, Bernd Gruhn15, Franco Locatelli16, Stefano Giardino17, Anne Uyttebroeck18, Fanny Rialland19, Maija Itäla-Remes20, Peter Dreger21, Peter J Shaw22, Victoria Bordon23, Paul G Schlegel24, Karin Mellgren25, Jose M Moraleda26, Katharine Patrick27, Pascale Schneider28, Charlotte Jubert29, Anita Lawitschka30, Nina Salooja31, Grzegorz W Basak32, Selim Corbacioglu33, Rafael Duarte34, Peter Bader35.   

Abstract

Gonadal impairment is an important late effect with a significant impact on quality of life of transplanted patients. The aim of this study was to compare gonadal function after busulfan (Bu) or treosulfan (Treo) conditioning regimens in pre- and postpubertal children. This retrospective, multicenter study included children transplanted in pediatric European Society for Blood and Marrow Transplantation (EBMT) centers between 1992 and 2012 who did not receive gonadotoxic chemoradiotherapy before the transplant. We evaluated 137 patients transplanted in 25 pediatric EBMT centers. Median age at transplant was 11.04 years (range, 5 to 18); 89 patients were boys and 48 girls. Eighty-nine patients were prepubertal at transplant and 48 postpubertal. One hundred eighteen children received Bu and 19 Treo. A higher proportion of girls treated with Treo in the prepubertal stage reached spontaneous puberty compared with those treated with Bu (P = .02). Spontaneous menarche was more frequent after Treo than after Bu (P < .001). Postpubertal boys and girls treated with Treo had significantly lower luteinizing hormone levels (P = .03 and P = .04, respectively) compared with the Bu group. Frequency of gonadal damage associated with Treo was significantly lower than that observed after Bu. These results need to be confirmed in a larger population. Published by Elsevier Inc.

Entities:  

Keywords:  Busulfan; Gonadal damage; Pubertal stage; Treosulfan

Year:  2019        PMID: 31082473     DOI: 10.1016/j.bbmt.2019.05.005

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  15 in total

1.  Favorable outcomes of hematopoietic stem cell transplantation in children and adolescents with Diamond-Blackfan anemia.

Authors:  Brigitte Strahm; Felicia Loewecke; Charlotte M Niemeyer; Michael Albert; Marc Ansari; Peter Bader; Yves Bertrand; Birgit Burkhardt; Lydie M Da Costa; Alina Ferster; Alexandra Fischer; Tayfun Güngör; Bernd Gruhn; Ina Hainmann; Friedrich Kapp; Peter Lang; Ingo Müller; Ansgar Schulz; Amina Szvetnik; Marcin Wlodarski; Peter Noellke; Thierry Leblanc; Jean-Hugues Dalle
Journal:  Blood Adv       Date:  2020-04-28

2.  Targeted busulfan-based reduced-intensity conditioning and HLA-matched HSCT cure hemophagocytic lymphohistiocytosis.

Authors:  Matthias Felber; Colin G Steward; Karim Kentouche; Anders Fasth; Robert F Wynn; Ulrike Zeilhofer; Veronika Haunerdinger; Benjamin Volkmer; Seraina Prader; Bernd Gruhn; Stephan Ehl; Kai Lehmberg; Daniel Müller; Andrew R Gennery; Michael H Albert; Fabian Hauck; Kanchan Rao; Paul Veys; Moustapha Hassan; Arjan C Lankester; Jana Pachlopnik Schmid; Mathias M Hauri-Hohl; Tayfun Güngör
Journal:  Blood Adv       Date:  2020-05-12

Review 3.  Unresolved issues in allogeneic hematopoietic cell transplantation for non-malignant diseases.

Authors:  Katsutsugu Umeda
Journal:  Int J Hematol       Date:  2022-05-14       Impact factor: 2.490

4.  Busulfan-fludarabine- or treosulfan-fludarabine-based myeloablative conditioning for children with thalassemia major.

Authors:  Roswitha Lüftinger; Natalia Zubarovskaya; Christina Peters; Arjan Lankester; Selim Corbacioglu; Jacques-Emmanuel Galimard; Annamaria Cseh; Elisabeth Salzer; Franco Locatelli; Mattia Algeri; Akif Yesilipek; Josu de la Fuente; Antonella Isgrò; Amal Alseraihy; Emanuele Angelucci; Frans J Smiers; Giorgia La La Nasa; Marco Zecca; Tunc Fisgin; Emel Unal; Katharina Kleinschmidt
Journal:  Ann Hematol       Date:  2022-01-09       Impact factor: 3.673

5.  Prospective Study of a Novel, Radiation-Free, Reduced-Intensity Bone Marrow Transplantation Platform for Primary Immunodeficiency Diseases.

Authors:  Dimana Dimitrova; Juan Gea-Banacloche; Seth M Steinberg; Jennifer L Sadler; Stephanie N Hicks; Ellen Carroll; Jennifer S Wilder; Mark Parta; Lauren Skeffington; Thomas E Hughes; Jenny E Blau; Miranda M Broadney; Jeremy J Rose; Amy P Hsu; Rochelle Fletcher; Natalia S Nunes; Xiao-Yi Yan; William G Telford; Veena Kapoor; Jeffrey I Cohen; Alexandra F Freeman; Elizabeth Garabedian; Steven M Holland; Andrea Lisco; Harry L Malech; Luigi D Notarangelo; Irini Sereti; Nirali N Shah; Gulbu Uzel; Christa S Zerbe; Daniel H Fowler; Ronald E Gress; Christopher G Kanakry; Jennifer A Kanakry
Journal:  Biol Blood Marrow Transplant       Date:  2019-09-04       Impact factor: 5.742

Review 6.  Long Term Outcome and Immune Function After Hematopoietic Stem Cell Transplantation for Primary Immunodeficiency.

Authors:  Andrew R Gennery; Arjan Lankester
Journal:  Front Pediatr       Date:  2019-09-24       Impact factor: 3.418

7.  Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study.

Authors:  Christina Peters; Jean-Hugues Dalle; Franco Locatelli; Ulrike Poetschger; Petr Sedlacek; Jochen Buechner; Peter J Shaw; Raquel Staciuk; Marianne Ifversen; Herbert Pichler; Kim Vettenranta; Peter Svec; Olga Aleinikova; Jerry Stein; Tayfun Güngör; Jacek Toporski; Tony H Truong; Cristina Diaz-de-Heredia; Marc Bierings; Hany Ariffin; Mohammed Essa; Birgit Burkhardt; Kirk Schultz; Roland Meisel; Arjan Lankester; Marc Ansari; Martin Schrappe; Arend von Stackelberg; Adriana Balduzzi; Selim Corbacioglu; Peter Bader
Journal:  J Clin Oncol       Date:  2020-12-17       Impact factor: 44.544

Review 8.  Treosulfan-based conditioning for inborn errors of immunity.

Authors:  Mary A Slatter; Andrew R Gennery
Journal:  Ther Adv Hematol       Date:  2021-05-20

Review 9.  Conditioning Perspectives for Primary Immunodeficiency Stem Cell Transplants.

Authors:  Peter Shaw; Judith Shizuru; Manfred Hoenig; Paul Veys
Journal:  Front Pediatr       Date:  2019-11-06       Impact factor: 3.418

10.  Urogenital Abnormalities in Adenosine Deaminase Deficiency.

Authors:  Roberta Pajno; Lucia Pacillo; Salvatore Recupero; Maria P Cicalese; Francesca Ferrua; Federica Barzaghi; Silvia Ricci; Antonio Marzollo; Silvia Pecorelli; Chiara Azzari; Andrea Finocchi; Caterina Cancrini; Gigliola Di Matteo; Gianni Russo; Massimo Alfano; Arianna Lesma; Andrea Salonia; Stuart Adams; Claire Booth; Alessandro Aiuti
Journal:  J Clin Immunol       Date:  2020-04-19       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.